Trial Profile

A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levomilnacipran (Primary) ; Fluoxetine
Indications Major depressive disorder
Focus Registrational; Therapeutic Use
Sponsors Allergan; Forest Laboratories

Most Recent Events

01 Jun 2024 Primary endpoint has not been met (Change From Baseline in Childrens Depression Rating Scale-Revised (CDRS-R) Total Score) , according to Results published in the Journal of Child and Adolescent Psychopharmacology
01 Jun 2024 Results published in the Journal of Child and Adolescent Psychopharmacology
03 Sep 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com